Intrahepatic Cholangiocarcinoma
Showing NaN - NaN of 17
Intrahepatic Cholangiocarcinoma Trial in Shanghai (HMPL-453, Rabeprazole)
Active, not recruiting
- Intrahepatic Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaShanghai Xuhui Central Hospital
Jun 24, 2023
Intrahepatic Cholangiocarcinoma Trial in Shanghai (Cadonilimab+Gem/Cis)
Active, not recruiting
- Intrahepatic Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaEastern hepatobilliary surgery hospital
Mar 22, 2023
Intrahepatic Cholangiocarcinoma Trial in China, United States (Extend LymphAdenectomy)
Recruiting
- Intrahepatic Cholangiocarcinoma
- Extend LymphAdenectomy
-
Baltimore, Maryland
- +12 more
Nov 7, 2022
Intrahepatic Cholangiocarcinoma Trial in Shanghai (Toripalimab, Lenvatinib mesylate capsules, Placebo IV)
Not yet recruiting
- Intrahepatic Cholangiocarcinoma
- Toripalimab
- +6 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital affiliated to Fudan University
Aug 12, 2022
Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma Trial in China (Observation)
Recruiting
- Primary Liver Cancer
- +3 more
- Observation
-
Beijing, Beijing, China
- +4 more
Jun 14, 2022
Intrahepatic Cholangiocarcinoma Trial in Shanghai (Camrelizumab, US/CT-guided Percutaneous Cryoablation)
Recruiting
- Intrahepatic Cholangiocarcinoma
- Camrelizumab
- US/CT-guided Percutaneous Cryoablation
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Jun 1, 2022
Intrahepatic Cholangiocarcinoma Trial in Shanghai (GP+PD-1+Tight)
Withdrawn
- Intrahepatic Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaZhongshan hospital, Fudan University
Mar 22, 2022
Intrahepatic Cholangiocarcinoma Trial in Shanghai (Sintilimab, Lenvatinib)
Recruiting
- Intrahepatic Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 23, 2021
Intrahepatic Cholangiocarcinoma Trial in Shanghai (cryoablation, Sintilimab, lenvatinib)
Recruiting
- Intrahepatic Cholangiocarcinoma
- cryoablation
- +2 more
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 23, 2021
Intrahepatic Cholangiocarcinoma Trial in Shanghai (Tislelizumab, TACE)
Recruiting
- Intrahepatic Cholangiocarcinoma
- Tislelizumab
- TACE
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 13, 2021
Intrahepatic Cholangiocarcinoma Trial in Shanghai (Gemox combimed PD1 antibody)
Recruiting
- Intrahepatic Cholangiocarcinoma
- Gemox combimed PD1 antibody
-
Shanghai, Shanghai, ChinaZhongshan hospital
Jul 7, 2021
Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib Trial in Shanghai (Neoadjuvant treatment)
Recruiting
- Intrahepatic Cholangiocarcinoma
- +3 more
- Neoadjuvant treatment
-
Shanghai, Shanghai, ChinaZhongshan hospital
Jul 5, 2021
Intrahepatic Cholangiocarcinoma Trial in Shanghai (PD-1 blocking antibody SHR-1210, Capecitabine)
Recruiting
- Intrahepatic Cholangiocarcinoma
- PD-1 blocking antibody SHR-1210
- Capecitabine
-
Shanghai, Shanghai, China180 Fenglin Road
Sep 26, 2020
Intrahepatic Cholangiocarcinoma Trial in Shanghai (Bortezomib)
Recruiting
- Intrahepatic Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaEaster hepatobiliary surgery hospital
Nov 15, 2017
Intrahepatic Cholangiocarcinoma Trial in Shanghai (conventional lymph node dissection, unconventional lymph node dissection)
Unknown status
- Intrahepatic Cholangiocarcinoma
- conventional lymph node dissection
- unconventional lymph node dissection
-
Shanghai, Shanghai, ChinaEastern hepatobilliary surgery hospital
Mar 30, 2016
Intrahepatic Cholangiocarcinoma Trial in Shanghai (TACE+Tegafur, TACE)
Unknown status
- Intrahepatic Cholangiocarcinoma
- TACE+Tegafur
- TACE
-
Shanghai, Shanghai, ChinaEastern hepatobilliary surgery hospital
Mar 30, 2016
Intrahepatic Cholangiocarcinoma Trial in Shanghai (Resection, Radiotherapy)
Unknown status
- Intrahepatic Cholangiocarcinoma
- Resection
- Radiotherapy
-
Shanghai, Shanghai, ChinaEastern Hepatobiliary Surgery Hospital
Mar 30, 2016